ArticleWorld journal of surgical oncology2026
miR-4326 predicts adverse outcomes of triple-negative breast cancer and regulates cell growth and motility through modulating MED13.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is one of the most malignant subtypes of breast cancer with a high recurrence rate and adverse prognosis. Due to the lack of reliable molecular targets, improving patients' outcomes is still a challenge in the clinic. The clinical significance of miR-4326 and its potential in mediating tumor progression were investigated in this study, aiming to explore a novel biomarker for TNBC.
methodsA total of 108 patients diagnosed with TNBC were included in the present study, and the tissue samples were collected. The expression of miR-4326 was evaluated using PCR, while its clinical significance was assessed from the perspectives of disease severity and 5-year prognosis. In vitro, the regulation of TNBC cell growth and motility by miR-4326 was evaluated by CCK8 and Transwell assays with the help of cell transfection.
resultsUpregulation of miR-4326 was observed in tumor tissues of TNBC patients, which indicates advanced TNM stage, the occurrence of lymph node metastasis, and poorer prognosis. In TNBC cells, miR-4326 was also upregulated, its knockdown significantly suppressed cell proliferation, migration, and invasion. MED13 showed opposite dysregulation and was negatively regulated by miR-4326. Silencing MED13 could reverse the suppressive effect of miR-4326 knockdown on TNBC cells.
conclusionsmiR-4326 could serve as a prognostic biomarker for TNBC and regulate tumor progression via targeting MED13.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.